The cost of care associated with progression to metastatic prostate cancer is an important outcome. The economic burden of progression to metastatic disease should be considered in assessments of the value of early prostate cancer detection and treatment. See also pages 000-000.
http://ift.tt/2qLDe3B
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου